Isofol Medical AB (publ) has taken note of the results from the Modelle 001 study
GOTHENBURG, Sweden, October 5, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), announces today that the company has taken notice of the results from the investigator-initiated study Modelle 001.
The information in the press release is intended for investors.
As previously informed, Sahlgrenska University Hospital in collaboration with Norrland University Hospital has conducted an investigator-initiated academic study, Modelle 001. The study included 30 patients and was led by Dr. Helena Taflin at Sahlgrenska University Hospital in Gothenburg. The aim of the study was to examine in detail the effect of different folates (arfolitixorin/leucovorin) in combination with 5-FU on patients with colorectal cancer that has metastasized to the liver.
The research team presented the final study results at the Folate Receptor Society’s 8th International Symposium on Folate Biology and Therapeutics in New York on 4 October 2023. The abstract is published via Sahlgrenska University Hospital:
https://www.gu.se/sites/default/files/2023-10/Abstract%20%20FRS%20meeting%20H%20Taflin1_0.pdf
”This is an investigator-initiated academic study where the main purpose was to study the effect of different folates on the inhibition of the enzyme thymidylate synthase (TS) in the tumour, in this case liver metastases, where a new method that needs to be validated has been used. No clinical parameters in terms of efficacy have been evaluated as only one dose was given to the limited number of patients included in the study. We see the results as a possible complement to our previously conducted pharmacodynamic (PD) and pharmacokinetic (PK) study from 2015, where the same research group was involved, however, we need to quality review the material when a study report is available”, says acting CEO Roger Tell.
For more information, please contact
Isofol Medical AB (publ)
Roger Tell, acting Chief Executive Officer
E-mail: [email protected]
Phone: +46 (0) 760 29 39 11
The information was submitted for publication, through the agency of the contact person set out above, at 15:30 CEST on October 5, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
